Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Part of paid clinical trials in Palo Alto, California.

Sponsor
Stanford University
Study ID
NCT06080061
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Hypofractionated accelerated radiation therapy — RADIATION
    Hypofractionated accelerated radiation therapy

Study Details

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Key Dates

Start date
Oct 25, 2023
Status verified
Apr 2026
Primary completion
Nov 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
45 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Hypofractionated accelerated radiation therapy (HART)
    Patients will either be treated with 60-66 Gy in 30, 25, or 20 fractions based on ability to meet constraints to key organs at risk

Primary Outcome Measure

Dose limiting pulmonary and esophageal toxicity [ Time Frame: 9 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Stanford UniversityPalo AltoCalifornia94305
Aastha Dubey
[email protected]
650-725-2084
Sonya Boyd
[email protected]
650-723-2732
Joseph A Jaoude, MD (PRINCIPAL_INVESTIGATOR)
Stanford Cancer Center South BaySan JoseCalifornia95124
Aastha Dubey
[email protected]
650-725-2084
Sonya Boyd
[email protected]
650-723-2732
Joseph A Jaoude, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Palo Alto, CA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Stanford University· Palo Alto, CAStanford Cancer Center South Bay· San Jose, CA

Related Studies